Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-10-14
Study Completion Date
2025-09-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Immunotherapeutic approaches targeting immune checkpoint proteins PD-1/PD-L1 have recently demonstrated clinical efficacy in several cancer types, and have changed the therapeutic landscape in metastatic melanoma or non-small cell lung cancer (NSCLC).
The monoclonal anti-PD-1 antibody nivolumab has been registered by both FDA (Food and Drug Administration) and EMA (European Medicine Agency), for metastatic NSCLC patients, after failure of a prior platinum-based chemotherapy.
The approval was based on the results of phase III clinical trials in metastatic NSCLC. But all the trials only enrolled patients with good general condition, PS (Performance Status) 0 or 1. However, the prevalence of poor PS patients at time of diagnosis is high in lung cancer patients.
For patients with metastatic NSCLC and PS 3, there is no standard treatment except best supportive care, since all trials that accrued unselected PS 3 patients fail to prove any survival advantage, and most PS \>3 patients die within 2 to 4 months from diagnosis. Indeed, these patients are currently excluded from clinical trials. Specific dedicated clinical trials and treatment guidelines for this patient population are urgently needed, taking into account for the high prevalence of such patients.
The monoclonal anti-PD-1 antibody nivolumab has been registered by both FDA (Food and Drug Administration) and EMA (European Medicine Agency), for metastatic NSCLC patients, after failure of a prior platinum-based chemotherapy.
The approval was based on the results of phase III clinical trials in metastatic NSCLC. But all the trials only enrolled patients with good general condition, PS (Performance Status) 0 or 1. However, the prevalence of poor PS patients at time of diagnosis is high in lung cancer patients.
For patients with metastatic NSCLC and PS 3, there is no standard treatment except best supportive care, since all trials that accrued unselected PS 3 patients fail to prove any survival advantage, and most PS \>3 patients die within 2 to 4 months from diagnosis. Indeed, these patients are currently excluded from clinical trials. Specific dedicated clinical trials and treatment guidelines for this patient population are urgently needed, taking into account for the high prevalence of such patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%
NCT03808480
Non-small Cell Lung Cancer
UNKNOWN
PHASE2
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
NCT03469960
Non-Small Cell Lung Cancer Metastatic
COMPLETED
PHASE3
1st Line Durvalumab in PS 2 NSCLC Patients
NCT03620669
NSCLC Stage IV
NSCLC Stage IIIB
ACTIVE_NOT_RECRUITING
PHASE2
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
NCT02879617
Non-Small Cell Lung Cancer NSCLC
COMPLETED
PHASE2
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
NCT04991025
Lung Cancer
Lung Cancer Stage II
Lung Cancer Stage III
RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Non-small Cell Lung Cancer Stage IV
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Immunotherapy
Durvalumab 1500 mg every 4 weeks until the progression of disease, discontinuation due to toxicity or withdrawal of consent, for a maximum duration of 2 years.
Group Type
EXPERIMENTAL
Durvalumab
Intervention Type
DRUG
1500 mg IV every 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Durvalumab
1500 mg IV every 4 weeks
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subjects must have signed and dated an IEC (Independent Ethic Committee) approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.
Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.
2. Histologically or cytologically-proven NSCLC (squamous or non-squamous). If the diagnosis is cytologically-proven, sufficient material is necessary with at least 100 tumor cells evaluated for PD-L1 IHC (Immunohistochemistry).
3. PD-L1 expression ≥25% of tumor cells as assessed by the local pathology laboratory using protocols validated.
4. Available tumor samples for centralized PD-L1 immunohistochemistry analysis.
5. No EGFR (Epidermal Growth Factor Receptor) mutation and no ALK(Anaplasic Lymphoma Kinase) gene rearrangement.
6. Stage IV (8th classification TNM) M1a or M1b or M1c.
7. ECOG (Eastern Cooperative Oncology Group) PS = 2 or 3 despite optimal symptomatic treatment.
8. Body weight \>30kg
9. No prior systemic anticancer therapy (chemotherapy, immunotherapy including durvalumab, or EGFR or ALK inhibitors) given as primary therapy for advanced or metastatic disease. Neoadjuvant or adjuvant chemotherapy is not considered as chemotherapy for advanced or metastatic disease.
10. Limited field of radiation for palliation within 2 weeks of the first dose of durvalumab is allowed, provided the lung is not in the radiation field and irradiated lesion(s) cannot be used as target lesions.
11. Age 18-75 years.
12. Measurable tumor disease by CT per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
13. Life expectancy \> 8 weeks according to the investigator opinion.
14. Adequate biological functions:
neutrophils ≥ 1500/mm3 ; platelets ≥ 75 000/mm3 ; Hemoglobin ≥ 9 g/dL ; Creatinine Clearance \> 40 mL/min , AST and ALT ≤ 2,5 ULN unless liver metastases are present, AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤ 5 x ULN, serum bilirubin ≤ 1.5 x ULN except for patients with proved, Gilbert syndrome (≤ 5 x ULN) or patients with hepatic metastases (≤ 3 x ULN).
15. Other investigations detailed in Section 5 must have been performed within the timelines indicated.
16. Protocol treatment is to begin within 7 days of patient inclusion.
17. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
* Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
* Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \>1 year ago, had chemotherapy-induced menopause with last menses \>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
18. Females of childbearing potential who are sexually active with a nonsterilized male partner or men who are sexually active with women of childbearing potential must use a highly effective method of contraception prior the first dose of investigational product, and must agree to continue using such precautions for 90 days after the final dose of investigational product. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.
Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.
2. Histologically or cytologically-proven NSCLC (squamous or non-squamous). If the diagnosis is cytologically-proven, sufficient material is necessary with at least 100 tumor cells evaluated for PD-L1 IHC (Immunohistochemistry).
3. PD-L1 expression ≥25% of tumor cells as assessed by the local pathology laboratory using protocols validated.
4. Available tumor samples for centralized PD-L1 immunohistochemistry analysis.
5. No EGFR (Epidermal Growth Factor Receptor) mutation and no ALK(Anaplasic Lymphoma Kinase) gene rearrangement.
6. Stage IV (8th classification TNM) M1a or M1b or M1c.
7. ECOG (Eastern Cooperative Oncology Group) PS = 2 or 3 despite optimal symptomatic treatment.
8. Body weight \>30kg
9. No prior systemic anticancer therapy (chemotherapy, immunotherapy including durvalumab, or EGFR or ALK inhibitors) given as primary therapy for advanced or metastatic disease. Neoadjuvant or adjuvant chemotherapy is not considered as chemotherapy for advanced or metastatic disease.
10. Limited field of radiation for palliation within 2 weeks of the first dose of durvalumab is allowed, provided the lung is not in the radiation field and irradiated lesion(s) cannot be used as target lesions.
11. Age 18-75 years.
12. Measurable tumor disease by CT per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
13. Life expectancy \> 8 weeks according to the investigator opinion.
14. Adequate biological functions:
neutrophils ≥ 1500/mm3 ; platelets ≥ 75 000/mm3 ; Hemoglobin ≥ 9 g/dL ; Creatinine Clearance \> 40 mL/min , AST and ALT ≤ 2,5 ULN unless liver metastases are present, AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤ 5 x ULN, serum bilirubin ≤ 1.5 x ULN except for patients with proved, Gilbert syndrome (≤ 5 x ULN) or patients with hepatic metastases (≤ 3 x ULN).
15. Other investigations detailed in Section 5 must have been performed within the timelines indicated.
16. Protocol treatment is to begin within 7 days of patient inclusion.
17. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
* Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
* Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \>1 year ago, had chemotherapy-induced menopause with last menses \>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
18. Females of childbearing potential who are sexually active with a nonsterilized male partner or men who are sexually active with women of childbearing potential must use a highly effective method of contraception prior the first dose of investigational product, and must agree to continue using such precautions for 90 days after the final dose of investigational product. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.
Exclusion Criteria
1. Pure or combined SCLC.
2. Known HER2 (Human Epidermal Growth Factor Receptor), B-Raf, activating tumor mutations, or exon 14 c-MET splice mutations (mesenchymal-epithelial transition), or known ROS1 gene rearrangement.
3. Asymptomatic or symptomatic brain metastasis.
4. Carcinomatous meningitis.
5. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[e.g., colitis or Crohn's disease\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\]). The following are exceptions to this criterion:
* Patients with vitiligo or alopecia
* Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
* Any chronic skin condition that does not require systemic therapy
* Patients without active disease in the last 5 years may be included but only after consultation with IFCT
* Patients with celiac disease controlled by diet alone
6. Immunosuppressive treatment including systemic treatment with corticosteroids with greater dose than 10 mg prednisone equivalent daily, within 15 days before enrollment. Inhaled, nasal or topic corticosteroids are allowed.
7. History of allogenic organ transplantation.
8. Stage 4 (very severe, FEV1 (forced expiratory volume at one second) \<30% predicted) chronic obstructive pulmonary disease (COPD) according to GOLD classification.
9. NYHA (New York Heart Association) class 4 chronic heart failure
10. Pre-existing interstitial lung.
11. History of another primary malignancy except for :
* Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of IP (Investigational Product) and of low potential risk for recurrence
* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
* Adequately treated carcinoma in situ without evidence of residual disease Patients with a prostate adenocarcinoma history within the previous 5 years could be included in case of localized prostate cancer.
12. Living attenuated vaccine received within the 30 previous days.
13. Received any other experimental treatment or participation to any other therapeutic clinical trial.
14. Known allergy or hypersensitivity to any of the study drug or any of the study drug excipients.
15. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
16. Major surgical procedure within 28 days prior to the first dose of IP or planned surgical procedure during treatment.
17. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs (Adverse Events) or compromise the ability of the patient to give written informed consent.
18. Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen (HBsAg) result) and hepatitis C,. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. History of active tuberculosis or evident primo-infection for which there is no record or evidence of an active anti-tuberculous treatment (please consult IFCT in case of doubt).
19. Patient with human immunodeficiency virus (positive HIV ½ antibodies)
20. Any condition that, in the opinion of investigator, could compromise the adherence to treatment and follow-up.
21. Mental illness or psychological condition, which in the opinion of investigator could compromise the expression of the informed consent.
22. No public health insurance.
2. Known HER2 (Human Epidermal Growth Factor Receptor), B-Raf, activating tumor mutations, or exon 14 c-MET splice mutations (mesenchymal-epithelial transition), or known ROS1 gene rearrangement.
3. Asymptomatic or symptomatic brain metastasis.
4. Carcinomatous meningitis.
5. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[e.g., colitis or Crohn's disease\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\]). The following are exceptions to this criterion:
* Patients with vitiligo or alopecia
* Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
* Any chronic skin condition that does not require systemic therapy
* Patients without active disease in the last 5 years may be included but only after consultation with IFCT
* Patients with celiac disease controlled by diet alone
6. Immunosuppressive treatment including systemic treatment with corticosteroids with greater dose than 10 mg prednisone equivalent daily, within 15 days before enrollment. Inhaled, nasal or topic corticosteroids are allowed.
7. History of allogenic organ transplantation.
8. Stage 4 (very severe, FEV1 (forced expiratory volume at one second) \<30% predicted) chronic obstructive pulmonary disease (COPD) according to GOLD classification.
9. NYHA (New York Heart Association) class 4 chronic heart failure
10. Pre-existing interstitial lung.
11. History of another primary malignancy except for :
* Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of IP (Investigational Product) and of low potential risk for recurrence
* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
* Adequately treated carcinoma in situ without evidence of residual disease Patients with a prostate adenocarcinoma history within the previous 5 years could be included in case of localized prostate cancer.
12. Living attenuated vaccine received within the 30 previous days.
13. Received any other experimental treatment or participation to any other therapeutic clinical trial.
14. Known allergy or hypersensitivity to any of the study drug or any of the study drug excipients.
15. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
16. Major surgical procedure within 28 days prior to the first dose of IP or planned surgical procedure during treatment.
17. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs (Adverse Events) or compromise the ability of the patient to give written informed consent.
18. Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen (HBsAg) result) and hepatitis C,. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. History of active tuberculosis or evident primo-infection for which there is no record or evidence of an active anti-tuberculous treatment (please consult IFCT in case of doubt).
19. Patient with human immunodeficiency virus (positive HIV ½ antibodies)
20. Any condition that, in the opinion of investigator, could compromise the adherence to treatment and follow-up.
21. Mental illness or psychological condition, which in the opinion of investigator could compromise the expression of the informed consent.
22. No public health insurance.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intergroupe Francophone de Cancerologie Thoracique
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Valérie GOUNANT
Role: STUDY_CHAIR
AP-HP Hôpital Bichat-Claude Bernard
Michael DURUISSEAUX
Role: STUDY_CHAIR
Hospices Civils de Lyon - Hôpital Louis Pradel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Besançon - CHU
Besançon, , France
Site Status
Hôpital Ambroise Paré - Pneumologie
Boulogne, , France
Site Status
Caen - CHU Côte de Nacre
Caen, , France
Site Status
CH
Colmar, , France
Site Status
CHRU Grenoble
Grenoble, , France
Site Status
Centre Hospitalier - Pneumologie
Le Mans, , France
Site Status
CHRU de Lille
Lille, , France
Site Status
AP-HM Hopital Nord
Marseille, , France
Site Status
Montpellier - CHRU
Montpellier, , France
Site Status
GRH Mulhouse Sud-Alsace
Mulhouse, , France
Site Status
Nancy - Institut de Cancérologie de Lorraine
Nancy, , France
Site Status
Nantes - ICO Site René Gauducheau
Nantes, , France
Site Status
CHR d'Orléans La Source
Orléans, , France
Site Status
AP-HP Hopital Tenon - Pneumologie
Paris, , France
Site Status
Paris - APHP Bichat
Paris, , France
Site Status
Paris - Curie
Paris, , France
Site Status
Lyon - URCOT
Pierre-Bénite, , France
Site Status
CHU Strasbourg
Strasbourg, , France
Site Status
CHU Toulouse - Pneumologie
Toulouse, , France
Site Status
CHU Tours - Pneumologie
Tours, , France
Site Status
Countries
Review the countries where the study has at least one active or historical site.
France
Related Links
Access external resources that provide additional context or updates about the study.
http://www.ifct.fr
IFCT website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IFCT-1802
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer
NCT03030131
TERMINATED
PHASE2
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
NCT06498635
RECRUITING
PHASE3
Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.
NCT05937906
RECRUITING
PHASE1/PHASE2
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
NCT04255836
UNKNOWN
PHASE2
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
NCT04023617
UNKNOWN
PHASE2
Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer
NCT04858204
COMPLETED
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
NCT04249362
COMPLETED
PHASE2
Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial
NCT04432142
ACTIVE_NOT_RECRUITING
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
NCT05856695
ACTIVE_NOT_RECRUITING
PHASE2
Phase II Trial of Continuation Therapy in Advanced NSCLC
NCT03083808
COMPLETED
PHASE2
Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
NCT03023904
WITHDRAWN
PHASE2
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
NCT02434081
COMPLETED
PHASE2
Pembrolizumab for Advanced NSCLC and PS 2-3
NCT05589818
RECRUITING
PHASE2
Anti PD-1 Neo-adjuvant Treatment for NSCLC
NCT02938624
COMPLETED
PHASE1
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
NCT04465942
UNKNOWN
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879
ACTIVE_NOT_RECRUITING
PHASE3
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
NCT01721759
COMPLETED
PHASE2
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
NCT03801902
COMPLETED
PHASE1
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
NCT03059667
COMPLETED
PHASE2
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
NCT02659059
COMPLETED
PHASE2
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
NCT04026412
COMPLETED
PHASE3
Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2
NCT02733159
COMPLETED
PHASE2
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
NCT04716946
ACTIVE_NOT_RECRUITING
PHASE2
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
NCT03732664
COMPLETED
PHASE1
Lung Cancer With Copanlisib and Durvalumab
NCT04895579
COMPLETED
PHASE1